Cheng Chak Kwong, Huang Yu
School of Biomedical Sciences and Li Ka Shing Institute of Health Science; The Chinese University of Hong Kong, Hong Kong SAR 999077, China.
Heart and Vascular Institute and Shenzhen Research Institute, The Chinese University of Hong Kong, Hong Kong SAR 999077, China.
Med Rev (2021). 2021 Oct 21;1(1):23-46. doi: 10.1515/mr-2021-0002. eCollection 2021 Oct.
Our gut microbiome is constituted by trillions of microorganisms including bacteria, archaea and eukaryotic microbes. Nowadays, gut microbiome has been gradually recognized as a new organ system that systemically and biochemically interact with the host. Accumulating evidence suggests that the imbalanced gut microbiome contributes to the dysregulation of immune system and the disruption of cardiovascular homeostasis. Specific microbiome profiles and altered intestinal permeability are often observed in the pathophysiology of cardiovascular diseases. Gut-derived metabolites, toxins, peptides and immune cell-derived cytokines play pivotal roles in the induction of inflammation and the pathogenesis of dysfunction of heart and vasculature. Impaired crosstalk between gut microbiome and multiple organ systems, such as gut-vascular, heart-gut, gut-liver and brain-gut axes, are associated with higher cardiovascular risks. Medications and strategies that restore healthy gut microbiome might therefore represent novel therapeutic options to lower the incidence of cardiovascular and metabolic disorders.
我们的肠道微生物群由数万亿种微生物组成,包括细菌、古细菌和真核微生物。如今,肠道微生物群已逐渐被视为一个新的器官系统,它与宿主进行系统性和生化相互作用。越来越多的证据表明,肠道微生物群失衡会导致免疫系统失调和心血管稳态破坏。在心血管疾病的病理生理学中,经常观察到特定的微生物群特征和肠道通透性改变。肠道衍生的代谢产物、毒素、肽和免疫细胞衍生的细胞因子在炎症诱导以及心脏和血管功能障碍的发病机制中起关键作用。肠道微生物群与多个器官系统(如肠-血管、心-肠、肠-肝和脑-肠轴)之间的串扰受损与更高的心血管风险相关。因此,恢复健康肠道微生物群的药物和策略可能代表降低心血管和代谢紊乱发病率的新型治疗选择。